Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons by Goodwin, A.K. et al.
Behavioral effects and pharmacokinetics of gamma-
hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL)
and 1,4-butanediol (1,4-BD) in baboons
A. K. Goodwin and
Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University,
Baltimore, MD, USA
P. R. Brown
Departments of Molecular and Comparative Pathobiology and Surgery, School of Medicine, Johns
Hopkins University, Baltimore, MD, USA
E. E. W. Jansen and C. Jakobs
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The
Netherlands
K. M. Gibson and
Departments of Pediatrics, Pathology and Human Genetics, School of Medicine, University of
Pittsburgh, Pittsburgh, PA, USA
E. M. Weerts
Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University,
Baltimore, MD, USA
Abstract
Rationale—Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are prodrugs for gamma-
hydroxybutyrate (GHB). Like GHB, GBL and 1,4-BD are drugs of abuse, but their behavioral effects
may differ from GHB under some conditions.
Objectives—The first study compared the behavioral effects of GBL (32−240 mg/kg) and 1,4-BD
(32−240 mg/kg) with each other and to effects previously reported for GHB (32−420 mg/kg). A
second study determined GHB pharmacokinetics following intragastric administration of GHB,
GBL, and 1,4-BD.
Methods—Operant responding for food, observed behavioral effects, and a fine-motor task
occurred at multiple time intervals after administration of drug or vehicle. In a separate
pharmacokinetics study, blood samples were collected across multiple time points after
administration of GHB, GBL, and 1,4-BD.
Results—Like GHB, GBL, and 1,4-BD impaired performance on the fine-motor task, but the onset
of motor impairment differed across drugs. GBL and 1,4-BD dose dependently decreased the number
of food pellets earned, but at lower doses than previously observed for GHB. Similar to GHB, both
GBL and 1,4-BD produced sedation, muscle relaxation, gastrointestinal symptoms, and tremors/
jerks. Administration of GBL and 1,4-BD produced higher maximum concentrations of GHB with
shorter times to maximum concentrations of GHB in plasma when compared to GHB administration.
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Conclusions—GBL and 1,4-BD produced behavioral effects similar to those previously reported
with GHB and the time course of effects were related to blood levels of GHB. Given their higher
potency and faster onset of effects, the abuse liability of GBL and 1,4-BD may be greater than GHB.
Keywords
GABA; Behavior; Drug abuse; Operant
Gamma-hydroxybutyrate (GHB) is a drug of abuse and a prescribed treatment for narcolepsy
under the name Xyrem (sodium oxybate). Gamma-butyrolactone (GBL) and 1,4-butanediol
(1,4-BD) are GHB precursors that are metabolized into GHB after ingestion, although via
different pathways (Arena and Fung 1980; Barker et al. 1985; Lettieri and Fung 1978; Maxwell
and Roth 1972; Roth and Giarman 1965, 1968; Snead et al. 1989). GBL is metabolized to GHB
via serum lactonase. 1,4-BD is metabolized in a two-step conversion via alcohol
dehydrogenase, which first converts it to gamma-hydroxybutyraldehyde and then to GHB. The
behavioral effects of GBL and 1,4-BD are likely associated with their conversion to GHB
(Shannon and Quang 2000).
Following the scheduling of GHB, illicit use of GHB precursors increased (Palmer 2004). GBL
can be found in products including fingernail polish remover, pesticides, ink jet cleaner, and
various industrial solvents, while 1,4-BD is found in hair tonics and is used in the synthesis of
resins, polyurethanes, and GBL. Using instructions easily found on the Internet, GBL is often
converted to GHB prior to ingestion and it has been marketed on the internet as a safe alternative
to GHB (Ingels et al. 2000; Shannon and Quang 2000; Winickoff et al. 2000). Recreational
users of GHB, GBL, and 1,4-BD generally report feelings of euphoria, relaxation, drowsiness,
and disinhibition, although adverse effects, such as nausea, vomiting, anxiety, dizziness,
agitation, respiratory depression leading to coma, and sometimes death, are also reported
(Galloway et al. 2000; Miotto et al. 2001; Teter and Guthrie 2001).
It is unclear if the behavioral effects of GBL and 1,4-BD are entirely due to their conversion
to GHB in vivo, and studies examining possible differences in the behavioral effects of GHB,
GBL, and 1,4-BD in rodents have reported inconsistent results. Two studies examining the
discriminative stimulus effects of GHB reported GBL failed to produce discriminative stimulus
effects that substituted for those of GHB in rats (Carter et al. 2003; Winter 1981). Baker and
colleagues (2005), however, reported that both GBL and 1,4-BD fully substituted for GHB. In
addition, 1,4-BD and GHB substituted for GBL in a second group of rats trained to discriminate
GBL from vehicle (Baker et al. 2005). Rodent studies also suggest that GHB, GBL, and 1,4-
BD may differentially effect locomotor behavior (Davies 1978; de Fiebre et al. 2004) and the
onset and duration of action of the three compounds in rodents differ (Carter et al. 2003). In
addition, GBL significantly increased acetylcholine in rat striatum, hippocampus, and cortex
while GHB did not (Ladinsky et al. 1983). When tested in a food-maintained operant procedure,
GBL decreased response rate 90 min after administration while 1,4-BD did not suppress
responding until 150 min after administration (McMahon et al. 2003). Both GHB and GBL
produced physical dependence and had similar withdrawal syndromes after chronic
administration in baboons (Goodwin et al. 2006; Weerts et al. 2005). A comparison of the acute
behavioral effects and pharmacokinetics of GHB, GBL, and 1,4-BD has not been evaluated in
nonhuman primates.
The present study sought to characterize and compare the acute behavioral effects of GBL and
1,4-BD with each other and to previously collected GHB behavioral data in baboons (Goodwin
et al. 2005). Following drug administration, effects on food-maintained operant behavior, fine-
motor skills, and observed behaviors were determined across multiple time points. In addition,
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a second study examined pharmacokinetic parameters of GHB, GBL, and 1,4-BD following
intragastric administration.
Materials and methods
Subjects
Subjects were five adult male baboons (Papio anubis; primate imports, New York, NY, USA
and Southwest Foundation for Biomedical Research, San Antonio, TX, USA) that weighed
between 20 and 31 kg at the beginning of the study. Each baboon had a chronic indwelling
intragastric (IG) catheter implanted using procedures described previously (Lukas et al.
1982). The catheter was protected by a tether/harness/vest system that permitted the baboon-
free movement inside the cage.
Four of the baboons (PF, WL, HA, KH) had previously been subjects in studies examining the
acute and chronic effects of GHB (Goodwin et al. 2005; Weerts et al. 2005), but had not
received chronic drug for at least 2 months prior to acute administration of GBL. After
participating in the present study examining the acute behavioral effects of GBL, all four
baboons were subjects in a study examining the dependence potential of chronically
administered GBL (Goodwin et al. 2006). Prior to the start of acute administration of 1,4-BD,
baboons had not been exposed to chronically administered GBL for at least 3 months. A fifth
baboon (GR) was used in the pharmacokinetics studies.
Baboons had continuous access to tap water from a drinking spout located on the front of their
home cage and 20 h/day access to food pellets (1 g banana flavored, Bio-SERV, Inc.,
Frenchtown, NJ, USA or P.J. Noyes, Lancaster, NH, USA) as described below. Baboons also
received supplemental feeding with one or two pieces of fresh produce and a multivitamin at
the same time each day (noon). Every 2−3 weeks, baboons were anesthetized with ketamine
HCl (preceded by atropine sulfate) in order to allow physical examinations, catheter care,
weighing, and cage washing. The protocol was approved by the Johns Hopkins University
Animal Care and Use Committee and followed the “Guide for the Care and Use of Laboratory
Animals” (1996). Facilities were maintained in accordance with United States Department of
Agriculture and American Association for Laboratory Animal Care standards.
Apparatus
Subjects were individually housed in standard stainless steel primate cages that also served as
the experimental chambers. Cages were equipped with a bench that ran along a side wall and
an “intelligence panel” on the rear wall that contained a Lindsley operandum, a colored stimulus
light (“jewel light”), a food hopper for pellet delivery, and a speaker for delivery of a stimulus
tone as described previously (Weerts et al. 1998). The overhead lights in the room were
illuminated for 13 h/day (6:00 AM–7:00 PM) and were dimly illuminated for the remaining 11 h/
day.
Catheters were connected to an 18-gauge liquid swivel with a strain relief mount (Model
SR-750B, Instech-Soloman, Plymouth Meeting, PA, USA). Approximately 500−550 ml of
distilled water was slowly infused (0.3 ml/min) via a peristaltic pump (Harvard Model 1201
or 1203, Harvard Apparatus, S. Natick, MA, USA) over 24 h to maintain catheter patency.
Operant behavior sessions were controlled using IBM compatible personal computers with
Med-PC software and instrumentation (Med Associates, Inc., East Fairfield, VT, USA).
Observational data were collected using laptop computers with The Observer software (Noldus
Information Technology, Wageningen, The Netherlands).
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Drugs
GBL and 1,4-BD stock solutions were purchased from Sigma-Aldrich (St. Louise, MO, USA)
in concentrations of 1.17 g/ml for 1,4-BD,and 1.12 g/ml for GBL. For drug administration,
GBL and 1,4-BD grams per milliliter stock solutions were diluted with reoxidized water so
that the total dose (grams) for each baboon was administered in 150 ml. Each dose of GBL,
1,4-BD, or vehicle was administered as a single bolus infusion via the IG catheter at 9:00 AM
(±30 min). Doses of GBL (32−240 mg/kg) and 1,4-BD (32−240 mg/kg) were selected in order
to target doses comparable to those we used previously for GHB (32−320 mg/kg) and from
the relevant literature based on calculations using molecule weights of the different drug forms
(molar conversion) and interspecies dose conversions (Dews 1976; Mordenti and Chappell
1989). Doses (milligrams/kilogram) were progressively increased until disruption of food-
maintained behavior and sedation were observed in all subjects, and then, doses were repeated
in mixed order so that each dose was tested two to three times in each baboon; the mean of
these data was used for analysis. Drug was never given more than once every 3 days. A dose
of 240 mg/kg GBL was evaluated once in one baboon (HA) but resulted in convulsions and
so was not administered to any other subjects.
GHB sodium salt was used for the pharmacokinetics studies (Sigma-Aldrich, St. Louise, MO,
USA). Doses of GHB were calculated based on the salt and dissolved in reoxidized water to a
final volume of 150 ml and then administered as described for GBL and 1,4-BD.
Behavioral procedures
Food-maintained operant behavior procedure—Food pellets were available for 20 h/
day and contingent upon completion of a fixed number of responses on the Lindsley operandum
(i.e., a fixed ratio schedule of reinforcement). Sessions began at 9:00 AM immediately after drug
or vehicle administration. Drug or vehicle was administered only if the number of pellets earned
on the previous day was within the range of the baseline condition. The start of each session
was signaled by a tone and the illumination of a jewel light above the lever. The fixed ratio
(FR) value was adjusted prior to beginning the experimental conditions so that (1) the number
of pellets delivered per day was stable (i.e., no increasing or decreasing trends) for at least 14
days, (2) virtually all pellets delivered per day were consumed (i.e., no more than two to three
pellets were found in the pans), and (3) the number of pellets delivered per day was sufficient
to maintain body weights in adult baboons of their size and activity level. Using these criteria,
the FR value maintained for the study was 10 for PF, WL, and HA and 5 for KH. Food-
maintained operant behavior data were collected in 2-h bins across the 20-h session. After 20
h had elapsed, all programmed stimuli were turned off and responses did not result in pellet
delivery. Cage pans were inspected and the number of pellets found, if any, was recorded in
the daily record.
Behavioral observation procedures—To characterize and compare behavioral effects
of GBL and 1,4-BD, trained observers completed a 30-min continuous observation session
using laptop computers; observations were initiated 60 min after administration of GBL or 1,4-
BD. The procedures were similar to those used previously such that results from the present
study could be easily compared to those of GHB (Goodwin and Weerts 2005). Briefly, a trained
observer recorded the frequency and duration of all behaviors and postures (as defined in
Weerts et al. 1998)in “real time”. The behaviors and postures have been used previously in our
laboratory to characterize the behavioral effects of GHB (Goodwin et al. 2005, 2006; Weerts
et al. 2005).
In addition, a paper and pencil checklist with an abbreviated list of behaviors was completed
at 30-min intervals before and after the 30-min continuous observation sessions until 4 h
postdrug administration (i.e., at 0.5, 2, 2.5, 3, 3.5, and 4 h). Checklists were then completed
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every hour until behaviors not typically observed during vehicle conditions (e.g., vomiting,
retching, ataxia, lip droop, tremors, and jerks) were no longer detected. Baboons were observed
for 5 min and observers recorded whether or not target behaviors were observed. In this way,
the onset and time to recover from overt drug effects (i.e., return to vehicle control) were
documented.
A total of seven people were used as observers and observers were not blind to treatment
conditions. Before the study began, 30-min continuous observation sessions were conducted
in which two observers recorded behavior for the same baboon at the same time on laptop
computers. Each observer completed observations with each of the other observers until the
concordance between observers for the frequency of all behaviors and postures that occurred,
as well as agreement on nonoccurrence of each behavior and posture, for these dual observation
sessions was greater than 90%. Interrater reliability was calculated using a frequency- and
sequence-based method provided as part of The Observer software (Noldus Information
Technology, Wageningen, The Netherlands). Reliability of 90% or greater among observers
for drug-induced behavior had also previously been determined in prior drug studies (Goodwin
et al. 2005, 2006; Weerts et al. 2005).
Fine-motor task—The effects of acutely administered GBL and 1,4-BD on fine-motor
coordination were assessed with a 2-min food item retrieval task as described previously
(Weerts et al. 1998). The food item used was based on each baboon's preference (shelled
peanuts or raisins). Once preference was determined, the same food item was used throughout
the study for each baboon. Briefly, one food item was placed in each of the six equally spaced
cups, and the tray was placed against the front of the cage. Observers recorded the duration
(seconds) to retrieve all six items, or the maximum time of 120 s, whichever occurred first.
Observers also recorded the number of items retrieved/dropped and specific comments about
behaviors observed during the task. Behavioral definitions were identical as described above.
Prior to drug administration, baboons completed the task daily until performance was stable.
On test days, the task was presented 30, 60, and 120 min after infusion of vehicle or drug.
Pharmacokinetics of GHB, GBL and 1,4-BD—Pharmacokinetic parameters of GHB,
GBL, and 1,4-BD were determined separately from the above behavioral experiments. Using
the same administration procedures as described above, doses of 32, 100, and 180 mg/kg of
GBL and 1,4-BD and doses of 32, 100, and 320 mg/kg of GHB were administered as a single
bolus infusion via the IG catheter. Doses were administered in mixed order across baboons.
To allow handling and blood collection, baboons were anesthetized with ketamine (200−300
mg) and approximately 5 ml of blood was collected from a saffenous vein of each baboon using
a vacutainer with a lithium-heparinized tube. Blood samples were collected at multiple time
points postdrug administration (30 min and 1, 2, 4, 6, and 24 h). After the induction dose of
ketamine, later time points (e.g., 2, 4, and 6 h) required very little ketamine administration
(e.g., 50 mg) due to the ongoing sedation from the experimental compounds and the previous
ketamine administration. After the initial analysis of the plasma data revealed peak levels of
GHB 6 h after 320 mg/kg GHB administration, additional time points were added for this dose
of GHB. Doses were repeated and blood was collected at 8, 10, and 12 h post-GHB dose
administration. After collection, all blood samples were immediately centrifuged at 3,200 rpm
for 12 min. The plasma was then drawn off and transferred to two separate polypropylene tubes
and frozen for subsequent analyses. Samples were shipped on dry ice via overnight mail to Dr.
Gibson's laboratory at the University of Pittsburgh and Dr. Jakobs Laboratory at VU University
Medical Center, Amsterdam, where they were stored at −70 until subsequent analysis. Levels
of GHB in plasma after GBL, 1,4-BD, and GHB administration were determined using isotope
dilution gas chromatography–mass spectrometry (GCMS): Isotope dilution GCMS is an
accepted and common practice for accurate quantification of metabolites in tissue extracts and
physiological fluids (Gibson et al. 1990). The procedure includes addition of a known amount
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of isotopically labeled internal standard (deuterium or carbon-13, nonradioactive) prior to
analytical workup. Following administration of 1,4-BD, levels of 1,4-BD in plasma were
analyzed by comparable methodology using labeled 1,4-BD as internal standard. Levels of
GBL in plasma after GBL administration could not be quantified.
Data analyses
Food-maintained behavioral data were summarized as the number of pellets earned for each
of the ten 2-h time bins (e.g., 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 h postadministration of drug
or vehicle). Performance of the fine-motor task was summarized as duration of time (seconds)
to complete the task for each of the times conducted (30, 60, and 120 min postadministration
of drug or vehicle). Separate repeated measures two-way (drug dose vs. time since
administration) analyses of variance (ANOVA) were conducted for GBL and 1,4-BD to
compare the number of food pellets earned and the duration of time to complete the fine-motor
task across doses in each experiment. Significance was accepted at p<0.05. When a significant
effect was found, Bonferroni multiple comparison post-hoc t-tests were used to compare each
dose to vehicle. In addition, food-maintained behavior data previously collected for GHB
(Goodwin et al. 2005) were reanalyzed using the bin-by-bin summary of pellets per 2 h as in
the current study.
The 30-min continuous observation session data collected using a laptop computer were first
summarized as total frequency scores for behaviors, and total frequency and duration scores
for postures were recorded over the 30-min session. For data reduction of observed behaviors,
the frequency scores for some related behaviors (e.g., vomit and retch, tremor and jerk) were
added to yield a combined score. Frequency and duration scores of all observations were
analyzed using separate one-way ANOVAs to compare the frequency of each behavior and
the frequency and duration of each posture under drug conditions to vehicle in each experiment.
Bonferroni multiple comparison post-hoc t-tests were used when significance was found.
The data collected using the paper and pencil checklists are presented in table form such that
the number of subjects displaying the maximal effect for each behavior, the time to maximal
effect, the duration of effects, and the time to recovery of baseline are presented for the two
highest doses of GBL (100 and 180 mg/kg) and 1,4-BD (180 and 240 mg/kg).
Pharmacokinetic data were calculated using GraphPad Prism (San Diego, CA, USA) software.
The elimination half-life (T1/2) and area under the concentration–time curve (AUC) of 1,4-BD
in plasma after 1,4-BD administration were calculated, as was the T1/2 and AUC of GHB in
plasma after administration of each of the three compounds (GHB, GBL, and 1,4-BD). The
maximum concentrations (Cmax) in plasma postdrug administration and time to maximum
concentration (Tmax) were also determined.
Results
There were significant interactions between dose and time for GHB (F=3.49, p<0.0001), GBL
(F=5.50, p<0.0001), and 1,4-BD (F=3.38, p<0.0001) on food-maintained behavior. These
effects were dose-related and biphasic when compared to vehicle. Figure 1 shows the
significant effects of GHB (a), GBL (b), and 1,4-BD (c) on food-maintained behavior. GHB
data shown were reanalyzed from data from a previous study (Goodwin et al. 2005)to allow
direct comparison of changes in food-maintained behavior produced by GHB, GBL, and 1,4-
BD. Specifically, when compared to vehicle, 100 mg/kg GHB significantly increased food-
maintained behavior during the first 2 h after drug administration (p<0.05). Higher doses (320
and 420 mg/kg) of GHB significantly decreased food-maintained behavior during the first 2 h
after drug administration (p< 0.05). Food-maintained behavior was not significantly altered 4
h after GHB administration. For GBL, none of the doses increased food-maintained behavior.
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When compared to vehicle, food-maintained behavior was decreased by 100 and 180 mg/kg
2 h after drug administration (both p<0.001) and was also decreased 4 h after administration
of 180 mg/kg GBL (p<0.001). In the one subject (HA) that received a dose of 240 mg/kg of
GBL, food-maintained behavior was suppressed over the entire 20 h of food pellet availability
(data not shown). For 1,4-BD, increases in food-maintained behavior were also observed, but
at a lower dose (56 mg/kg) and not until 4 h after administration (p<0.05). When compared to
vehicle, higher doses (180 and 240 mg/kg) of 1,4-BD decreased food-maintained behavior 2
(both p<0.001) and 4 h postadministration (both p<0.05). Thus, there were differences in the
time course of effects on food-maintained behavior between the different compounds.
There were also differences between drugs in the onset of disruptive effects during the fine-
motor coordination task, as measured by increased duration of time to complete the task. Figure
2 shows the effects of GHB, GBL, and 1,4-BD on duration (seconds) to complete the fine-
motor task. Data shown for GHB (a) from a previous study (Goodwin et al. 2005) have been
replotted to allow direct comparison of the effects of GHB, GBL, and 1,4-BD on fine-motor
behavior. There was a significant dose × time interaction for GHB (F=9.53, p<0.0001). As
shown in Fig. 2, GHB did not alter duration to complete the task at any dose tested 60 min
postadministration. In contrast, 180−420 mg/kg GHB increased the duration to complete the
fine-motor task at 120 min postadministration. There was a significant main effect for GBL
dose (F=99.67, p<0.0001) on performance of the fine-motor task. Doses of 100 and 180 mg/
kg GBL increased duration to complete the task when compared to vehicle (p<0.001); there
was no interaction effect as dose-related increases in duration to complete the task were
observed across all times (30, 60, and 120 min postdrug administration). In contrast, there was
a significant dose × time interaction for 1,4-BD (F=27.99, p<0.0001). High doses of 1,4-BD
significantly increased duration to complete the fine-motor task at 60 (180 mg/kg) and 120 min
(180 and 240 mg/kg) postadministration (all p<0.001); at 240 mg/kg 1,4-BD, all subjects failed
to complete the task within the maximum time of 120 s. 1,4-BD did not alter the duration to
complete the fine-motor task at any dose 30-min postadministration.
Figure 3 illustrates the significant effects of GBL and 1,4-BD on behaviors recorded via laptop
computers during the 30-min continuous observation session. Due to significant differences
in how behavioral observation data were collected, data from the previous acute GHB study
(Goodwin et al. 2005) were not replotted for visual comparison with the GBL and 1,4-BD data.
There were significant main effects of GBL dose on the frequency of scratch/groom (F=10.15,
p<0.0001), vomit/retch (F=6.11, p<0.001), ataxia (F=19.76, p<0.0001), and tremor/jerks
(F=18.73, p<0.0001 for GBL) and on the duration of lip droop (F=17.95, p< 0.0001 for GBL)
and time spent lying down (F=3.31, p< 0.05). When compared to vehicle, 100 mg/kg GBL
significantly increased ataxia (p<0.0001), tremor/jerks (p< 0.0001), lip droop (p<0.001), and
scratch/groom (p<0.001). Scratch groom was then decreased at the 180 mg/kg dose of GBL
(p<0.01). Increases in ataxia (p<0.0001), tremor/jerks (p<0.0001), and lip droop (p<0.001)
were also significantly higher at 180 mg/kg GBL. In addition, duration of lying down (p<0.001)
and vomit/retch were increased by 180 mg/kg. A high dose of 240 mg/kg GBL administered
to one subject (HA) resulted in vomit/retch, ataxia, tremor/jerks, sedation/anesthesia, and
seizures at 2 h postadministration (data not shown). Other behaviors recorded but not shown
were not significantly changed.
As shown in Fig. 3, effects of 1,4-BD were very similar to those of GBL. There were significant
main effects of 1,4-BD dose on the frequency of scratch/groom (F=5.26, p< 0.001), vomit/
retch (F=7.16, p<0.001), ataxia (F=17.96, p<0.0001), tremor/jerks (F=5.79, p<0.0001),
duration of lip droop (F=30.06, p<0.0001), and time spent lying down (F=6.95, p<0.0001).
When compared to vehicle, 180 and 240 mg/kg 1,4-BD significantly increased frequency of
vomit/retch (both p<0.01), ataxia (both p<0.0001), and tremor/jerks (both p<0.0001). The
frequency of scratch/groom was also increased at 56 and 180 mg/kg 1,4-BD (p< 0.05). At 240
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mg/kg 1,4-BD, duration of lip droop and time lying down were also significantly increased
(all p<0.001). Other behaviors recorded but not shown were not significantly changed.
Examination of the paper and pencil behavioral checklists indicated that the onset of these
behavioral effects differed for GBL and 1,4-BD. In addition, the duration of behavioral effects
of GBL and 1,4-BD was dependent on the dose and behavioral measure. As shown in Table
1, time to maximal effect for ataxia and tremor/jerks was 30 min postadministration of 100 and
180 mg/kg GBL. Maximal effect for vomit/retch was observed at 1 h postadministration of
100 and 180 mg/kg GBL, and this behavior was not observed in any of the subsequent time
points. In contrast, maximal effects of 100 and 180 mg/kg GBL on ataxia were observed 30
min through 1 h after administration, and ataxia continued to be observed for 4 h in 50% of
the subjects administered with 180 mg/kg GBL. A return to baseline for these behaviors after
100 mg/kg GBL occurred sooner than the 180 mg/kg dose. For example, tremor/jerk was no
longer present by 2 h postadministration of 100 mg/kg GBL, but was observed in 50% of the
subjects 5 h postadministration of 180 mg/kg GBL. For 1,4-BD, maximal effects for ataxia,
tremor/jerk, and lip droop were observed 1−2 h after administration of the 240 mg/kg dose and
continued to be observed in 75% of the subjects 3−4 h postadministration. Maximal effects for
lip droop occurred at 1 (240 mg/kg) and 2 h (180 mg/kg) postadministration of 1,4-BD and
continued in half of the subjects at 2.5−3.5 h. Lip droop was no longer observed by 5 h
postadministration of 1,4-BD. Behavioral checklists were not completed when the acute effects
of GHB were studied previously (Goodwin et al. 2005).
Figure 4 shows plasma levels of GHB across time following administration of GHB (a), GBL
(b), and 1,4-BD (c) and plasma levels of 1,4-BD across time after administration of 1,4-BD
(d). As shown in Fig. 4, GBL and 1,4-BD were metabolized to GHB in the baboon and plasma
levels of GHB were increased in a dose-dependent manner for all three compounds. The time
after dosing to reach maximum concentrations (Tmax) of GHB in plasma was 30 min for the
lowest dose (32 mg/kg) of GHB, GBL, and 1,4-BD; 1 h for 100 mg/kg of GHB, GBL, and 1,4-
BD; and 2 h for 180 mg/kg GBL and 1,4-BD. The Tmax for the highest dose of GHB (320 mg/
kg), however, was 6 h. As shown in Fig. 4, the mean maximum concentration (Cmax) of GHB
in plasma was higher following administration of GBL across doses when compared to the
Cmax of GHB following administration of 1,4-BD or GHB. In contrast, the Tmax for plasma
levels of 1,4-BD was 30 min after acute administration of 1,4-BD (see Fig. 4d) and decreased
across time. Table 2 shows the pharmacokinetic parameters of GHB in plasma following
administration of GHB, GBL, and 1,4-BD. As shown in Table 2, there were some differences
in pharmacokinetic parameters of GHB in plasma following administration of GBL and 1,4-
BD. The GHB area under the curve following GBL administration was substantially greater
when compared to GHB area under the curve following GHB or 1,4-BD. There was also some
variability across subjects in metabolism of GBL and 1,4-BD to GHB, as shown by the wide
range of maximum concentrations of GHB in plasma that were observed. As shown in Table
3, the T1/2 of 1,4-BD in plasma was less than 1 h at the 100 and 180 mg/kg doses of 1,4-BD.
The T1/2 for GHB in plasma was five- and sevenfold longer than the T1/2 of 1,4-BD for 100
and 180 mg/kg 1,4-BD, respectively.
Discussion
The current data indicate the acute behavioral effects of GBL, and 1,4-BD are very similar to
those of GHB. The behavioral effects of the classic sedative hypnotic compounds (e.g.,
benzodiazepines and barbiturates) have often been compared to GHB. Indeed, similar to classic
sedative hypnotic compounds, GHB and its prodrugs increased behaviors indicative of motor
impairment (ataxia), sedation (lying down), and muscle relaxation (lip droop). GBL and 1,4-
BD also produced decreases in food-maintained behavior and impaired performance on the
fine-motor task, which is similar to effects observed in baboons treated with benzodiazepines
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(Ator et al. 2000; Weerts et al. 1998). GBL and 1,4-BD, however, also produce changes that
are distinctly different from benzodiazepines. For example, rather than the traditional sedation
observed with benzodiazepines, higher doses of GHB actually produce a cataleptic state (Itzhak
and Ali 2002; Navarro et al. 1998; Sevak et al. 2004). In the current study, both GBL and 1,4-
BD produced gastrointestinal symptoms (i.e., vomit/retch) and tremors/jerks. Tremor/jerks
were observed across a range of doses and a dose of 240 mg/kg of GBL given to one subject
produced both seizures and catalepsy. These effects have also been observed in baboons
administered with GHB (Goodwin et al. 2005) and in rhesus monkeys administered with GHB
and GBL (Snead 1978a, b, c). The proconvulsant effects of GHB and its prodrugs clearly
differentiate these compounds from classic sedative hypnotics.
Although GHB, GBL, and 1,4-BD produced similar behavioral effects, there were differences
in the onset and time course of effects. Interestingly, the onset of motor impairment was faster
for GBL when compared to 1,4-BD and GHB, and the onset of motor impairment for 1,4-BD
was faster when compared to GHB. Onset of sedation, muscle relaxation, and ataxia for GBL
was also faster when compared to 1,4-BD. Differences in onset of behavioral effects of GHB,
GBL, and 1,4-BD in baboons in the current study are consistent with reported results in other
species (Carter et al. 2003; de Fiebre et al. 2004). For example, McMahon et al. (2003) reported
that GBL had a more rapid onset of action on response rate when compared to 1,4-BD in rhesus
monkeys. In humans, the effects of GHB on psychomotor skills and changes in subject-reported
drug strength began as early as 30 min postadministration of high doses of GHB (8 g/70 kg)
but, similar to baboons, maximal drug effects of GHB were observed 1−2 h postadministration
(Carter et al. 2006). In addition to differences in the onset of action, the duration of action also
appears to vary somewhat between compounds. Drug-induced behavioral effects (e.g., ataxia,
vomit/retch, tremor/jerk, lip droop) were observed in at least half of the subjects from 0.5 to 5
h for GBL and from 1 to 6 h for 1,4-BD. At high doses, both drugs also suppressed food-
maintained behavior for 4 h after administration. The observed behavioral effects of GBL had
all returned to baseline by 6 h postadministration, while return to baseline for all behavioral
effects of 1,4-BD occurred 7−8 h postadministration.
The onset and duration of behavioral effects of GBL and 1,4-BD tracked concentrations of
GHB in plasma. In addition, the behavioral effects of 1,4-BD do not seem to be related to blood
levels of 1,4-BD detected in plasma. These findings are consistent with previous studies in
rodents that have reported the behavioral effects of GBL and 1,4-BD are not related to levels
of the prodrug in blood or brain, but are correlated with GHB levels (Giarman and Roth
1964; Guidotti and Ballotti 1970; Roth and Giarman 1968). Since GBL and 1,4-BD are
converted to GHB via different metabolic pathways, differences in onset and time course of
effects are likely related to differences in formation, elimination, and distribution in tissues
(Arena and Fung 1980; Irwin 1996). In addition, GBL is reportedly less polar and so is more
easily absorbed than its hydrolyzed free acid form (i.e., GHB; Irwin 1996) and is converted
into GHB so rapidly that there is a greater bioavailability of GHB after administration of GBL
when compared to an equivalent dose of GHB (Vree et al. 1978). Another factor that may
influence onset and time course of effects is that when administered orally or intragastrically,
GHB may inhibit its own absorption and disposition and/or be absorbed more slowly. The
differences in Cmax, Tmax, and T1/2 for the highest dose of GHB (320 mg/kg) in the current
study is suggestive of both of these possibilities.
In the current study, GBL appears to the most potent of the three compounds, followed by 1,4-
BD and then GHB. Consistent behavioral disruption (i.e., changes from baseline observed both
within and between subjects) in food-maintained behavior, fine-motor performance, and
observed behavior generally occurred at lower doses of GBL than for 1,4-BD. When similar
doses (32−180 mg/kg) were administered, GBL produced higher concentrations of GHB in
plasma than did 1,4-BD. The high conversion ratio of GBL to GHB is an important factor as
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ingestion of lower doses of GBL results in high blood levels of GHB and greater likelihood of
overdose.
A possible limitation to the generalization of these findings is the use of the N-methyl D-
aspartate (NMDA) receptor antagonist ketamine to anesthetize baboons and permit handling
for blood draws. It is possible that the plasma levels of GHB in plasma were altered by
ketamine. It has been previously reported that the NMDA receptor antagonist dizocilpine
significantly enhanced GHB-induced catalepsy in rats (Sevak et al. 2004), indicating NMDA
receptor antagonists may have an additive effect on behavior when given in combination with
GHB or related compounds. It is not known, however, if such effects are related to changes in
GHB pharmacokinetics or some other mechanism.
The previous pharmacokinetic studies in human subjects have evaluated 25−50 mg/kg GHB.
The typical therapeutic dose of GHB in humans is 37.5−112.5 mg/kg administered in two
divided doses and given 2−4 h apart (Cook 2003). For comparison, the 320 mg/kg dose of
GHB evaluated in the baboons would translate to an estimated 222-mg/kg acute dose in humans
using interspecies dose calculations (Dews 1976; Mordenti and Chappell 1989). Thus, the
doses examined in baboons for the current study included doses in the range of those used
therapeutically, as well as doses above the therapeutic range. When the concentrations of drug
measured in the different studies are converted to the same units of measure (micrograms/
milliliter), the pharmacokinetics of low doses of GHB in baboons and humans appear to be
similar. The time to maximum concentration and elimination half-life followed similar time
courses for both baboons and humans. Likewise, there is considerable individual variability in
the maximum concentrations of GHB in plasma. For example, the maximum concentration
ranged from 30 to 103 μg/ml human subjects administered total doses of 3−4.5 g GHB (i.e.,
42.8 mg/kg; Scharf et al. 1998). In other studies in which 50 mg/kg GHB was administered,
the mean maximum concentrations GHB in plasma ranged from to 20 (+7 standard deviation
(SD)) to 83.1 (+10.7 SD) μg/ml (Palatini et al. 1993 and Abanades et al. 2007, respectively).
Similarly, the 32 and 100 mg/kg doses of GHB in baboons produced mean maximum
concentrations of 18.46 (±8.66 SD) and 72.2 (±15.73 SD) μg/ml.
In humans, administration of 25 mg/kg 1,4-BD resulted in mean maximum concentrations of
3.84 μg/ml 1,4-BD (range 0.33−14.4) and 45.6 μg/ml GHB (range 22.2−85.7; Thai et al.
2006). In our study, a dose of 32 mg/kg 1,4-BD produced maximum concentrations ranging
from 0.48 to 0.69 μg/ml 1,4-BD and 8.07 to 24.24 μg/ml GHB. At higher doses, however, there
is a marked difference in the time to maximum concentration for GHB, GBL, and 1,4-BD. For
example, the time to maximum concentration after the 320 mg/kg dose of GHB was 6 h,
compared to an hour or less for the 32 and 100 mg/kg doses. Similar to human data, GHB
levels in plasma were dose dependent but nonlinear in the baboon. Indeed, it has been
demonstrated that both the absorption and elimination of GHB is dose dependent and nonlinear
(i.e., capacity limited; Lettieri and Fung 1979; Palatini et al. 1993; Shumate and Snead 1979).
Thus, although concentrations were slightly lower in the baboon, it seems reasonable to
conclude that the pharmacokinetics for GHB, GBL, and 1,4-BD were similar in the baboon,
as data fall within the range observed in a larger sample of human subjects. Given the higher
potency of GBL and 1,4-BD when compared to GHB and that both are metabolized into GHB
after ingestion, additional investigations of the pharmacokinetic and behavioral effects of high
doses of GHB, GBL, and 1,4-BD are warranted.
In conclusion, the current data suggest that GBL and 1,4-BD produce behavioral effects that
are similar to each other as well as to GHB, and these effects appear to be due to the conversion
of the prodrugs to GHB. Given that chronic administration of GBL produced physical
dependence (Goodwin et al. 2006) and that GBL and 1,4-BD were more potent with a quicker
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onset and a longer duration of action when compared to GHB, GBL, and 1,4-BD may have
greater abuse liability than GHB.
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Fig. 1.
Food-maintained behavior after administration of a GHB, b GBL, and c 1,4-BD. Data shown
are group means (±1 standard error of the mean) for the number of food pellets earned 2 and
4 h after administration of vehicle (V) or each drug dose (milligrams/kilogram). Data shown
are the number of pellets earned in each 2-h period and are not cumulative across time. *p<0.05
represents significant differences between a drug dose and vehicle in pair-wise post hoc tests
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Fig. 2.
Time to complete the fine-motor task following administration of a GHB, b GBL, and c 1,4-
BD. Data shown are group means (±1 standard error of the mean) for duration (seconds) to
complete the fine-motor task at 30, 60, and 120 min postadministration of vehicle (V) or each
drug dose (milligrams/kilogram). Data for GHB are replotted from Goodwin et al. (2005), and
the task was completed only at 60 and 120 min postadministration of GHB. *p<0.05 represents
significant interaction between a drug dose and vehicle at the same time (30, 60, or 120) as
determined in pair-wise post hoc tests
Goodwin et al. Page 15
Psychopharmacology (Berl). Author manuscript; available in PMC 2009 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 3.
Effects of GBL and 1,4-BD on behaviors recorded during the 30-min continuous observation
session using a laptop computer. During the session, the frequency and duration of all behaviors
that occurred were continuously recorded from 60 to 90 min after drug or vehicle (V) was
administered. Data shown are group means (±1 standard error of the mean) for frequency of
vomit/retch, ataxia, tremor/jerk, and scratch/groom and the duration (seconds) of lying down
and lip droop. *p<0.05 represents significant difference between a drug dose and vehicle as
determined by post hoc tests
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Fig. 4.
Plasma concentrations of GHB across time following administration of GHB (a), GBL (b),
and 1,4-BD (c) and plasma levels of 1,4-BD across time after administration of 1,4-BD (d).
Data shown are group means (±1 standard error of the mean) for concentrations (micromoles
per liter) of GHB (a–c) or 1,4-BD (d)
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Table 2
Pharmacokinetic parameters of GHB in plasma after acute intragastric doses of GHB, GBL, and 1,4-BD
Dose (mg/kg) GHB Cmax (μmol/l) GHB T1/2 (h) GHB AUC (mmol/l/h)
GHB
  32 mg/kg GHB 89.5−269.0 0.4218 379.5
  100 mg/kg GHB 485−820 1.716 1800
  320 mg/kg GHB 598−1942 12.17 4578
  32 mg/kg GBL 15−588 0.5394 423.8
  100 mg/kg GBL 757−2160 2.43 4865
  180 mg/kg GBL 1837−3183 8.673 21884
  32 mg/kg 1,4-BD 58.5−152 0 997
  100 mg/kg 1,4-BD 85.4−1370 3.266 2958
  180 mg/kg 1,4-BD 821−4330 5.658 12708
Data shown are the dose and drug administered, the range of maximum concentration (Cmax) of drug detected in plasma, the mean half-life (T1/2), and
AUC
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Table 3
Pharmacokinetic parameters of 1,4-BD in plasma following 1,4-BD administration
Dose (mg/kg) 1,4-BD Cmax (μmol/l) 1,4-BD T1/2 (h) 1,4-BD AUC (mmol/l/h)
1,4-BD
  32 mg/kg 1,4-BD 5.3−7.7 4.13 33.43
  100 mg/kg 1,4-BD 47.8−590 0.589 612.2
  180 mg/kg 1,4-BD 289−1104 0.7114 942
Data shown are the dose and drug administered, the range of maximum concentration (Cmax) of drug detected in plasma, the mean half-life (T1/2), and
AUC
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